Dr. Reddy's Laboratories announces the launch of Icosapent Ethyl Capsules, 1 gram in the U.S. Market

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced the launch of Icosapent Ethyl Capsules, 1 gram approved by the U.S. Food and Drug Administration (USFDA).

Dr. Reddy's Icosapent Ethyl Capsules, 1 gram is approved for the following indication: as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia.

Please note that Dr. Reddy's Icosapent Ethyl Capsules is not approved for the following indication: as an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization in adult patients with elevated triglyceride (TG) levels (≥ 150 mg/dL) and established cardiovascular disease or diabetes mellitus and two or more additional risk factors for cardiovascular disease.

Shares of DR.REDDY'S LABORATORIES LTD. was last trading in BSE at Rs.5279.6 as compared to the previous close of Rs. 5284.6. The total number of shares traded during the day was 28348 in over 3198 trades.

The stock hit an intraday high of Rs. 5298 and intraday low of 5225.95. The net turnover during the day was Rs. 148889580.

Source : Equity Bulls

Keywords